All EDCTP3 calls for proposals are also published on the European Commission’s Funding and Tender opportunities portal.
\
&
Contact us
\
&
Contact us
Partnership website: https://www.globalhealth-edctp3.eu/
The European & Developing Countries Clinical Trials Partnership (EDCTP) exists to accelerate the clinical development of new or improved health technologies for the identification, treatment and prevention of poverty-related and neglected infectious diseases, including (re-)emerging diseases.
The Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3) builds on the first and second EDCTP programmes and is a partnership between the EU and the EDCTP Association, whose members are several European and African countries.
The partnership will deliver new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.
The following organisations based in Flanders are partner in ongoing EDCTP3 projects (2022 & 2023 work programme):
Since it took off in 2022, EDCTP has launched several calls of proposals. Information on the latest calls for proposals can be found in the 2025 annual work programme. Any further information can be found on the EDCTP3 Calls for proposals webpage.
All EDCTP3 calls for proposals are also published on the European Commission’s Funding and Tender opportunities portal.
Partnership: EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
